Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Ob
Go back to Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Ob| (NASDAQ: DRTS) | Delayed: 13.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.01 | 52 Week High | $ | |||
| Open | $13.01 | 52 Week Low | $ | |||
| Day High | $13.01 | P/E | N/A | |||
| Day Low | $13.01 | EPS | $ | |||
| Volume | 13,922 | |||||
| (NASDAQ: DRTSW) | Delayed: 3.30 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.30 | 52 Week High | $ | |||
| Open | $3.30 | 52 Week Low | $ | |||
| Day High | $3.30 | P/E | N/A | |||
| Day Low | $3.30 | EPS | $ | |||
| Volume | 769 | |||||
